GLUE
Monte Rosa Therapeutics, Inc.
There isn't enough reported data to score GLUE yet.
GLUE Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
GLUE's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
GLUE PE Valuation
GLUE has no meaningful PE right now: it lost money over the past year.
GLUE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect GLUE's losses to grow, with revenue declining. However, they disagree widely on these estimates.
GLUE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.40 | -489% |
| Q2 2026 | -$1.76 | -540% |
| Q1 2026 | -$1.48 | -1333% |
| Q4 2025 | -$0.46 | +$0.52 |
| Q3 2025 | $0.36 | +$2.18 |
| Q2 2025 | $0.40 | +$2.63 |
| Q1 2025 | $0.12 | +$2.63 |
| Q4 2024 | -$0.98 | +$1.65 |
GLUE has swung to a loss: it lost $1.40 per share over the past year, after a profit the year before.
GLUE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $54.4M | +326% |
| Q2 2026 | $9M | -61% |
| Q1 2026 | $4.2M | -95% |
| Q4 2025 | $2.8M | -95% |
| Q3 2025 | $12.8M | +39% |
| Q2 2025 | $23.2M | +394% |
| Q1 2025 | $84.9M | +7882% |
GLUE's revenue is recovering but still below its 2025 peak: $54M last quarter, up 326% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3.6% | +255 points |
| Q2 2026 | -548% | -481 points |
| Q1 2026 | -1188% | -1240 points |
| Q4 2025 | -1788% | -1809 points |
| Q3 2025 | -258% | +30 points |
| Q2 2025 | -67% | +628 points |
| Q1 2025 | 52% | +3336 points |
| Q4 2024 | 21% | N/A |
GLUE's operating margin was −3.6% last quarter, up 255 points from the same quarter a year ago.
GLUE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$42.5M | -143% |
| Q2 2026 | -$48.8M | -$12.4M |
| Q1 2026 | -$39.2M | +$7.8M |
| Q4 2025 | -$43.8M | -134% |
| Q3 2025 | $99.8M | +$121.2M |
| Q2 2025 | -$36.4M | -$6.6M |
| Q1 2025 | -$47.1M | -$7.5M |
| Q4 2024 | $128.7M | +361% |
GLUE has burned cash in almost every quarter: −$174M over the past year, against $145M the year before.
GLUE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7% | +7.1M shares |
| 1 year | +32% | +26.2M shares |
| 3 years | +118% | +58.8M shares |
| 5 years | +155% | +66.1M shares |
| Available history | +400% | +86.9M shares |
GLUE has 109M diluted shares, up 32% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | $178,000 |
| Q1 2020 | — |
GLUE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -11.2x | Net Cash |
| Q2 2025 | -2.8x | Net Cash |
| Q1 2025 | -10.4x | Net Cash |
GLUE has more cash than debt.
GLUE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.0 | Neutral |
| Stochastic | 6.7 | Oversold |
GLUE's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
GLUE PE vs Healthcare Sector
| Metric | GLUE | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
GLUE has no meaningful PE right now: it lost money over the past year.
GLUE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.5 | 11% below |
| 20 week MA | $14.7 | 37% below |
| 50 week MA | $17.0 | 45% below |
| 100 week MA | $11.8 | 21% below |
| 200 week MA | $8.82 | 5.6% above |
GLUE has fallen below most of its moving averages, though it's still 5.6% above its 200-week average.
GLUE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $18.9 | $20.9 | +11% |
| 2022 | $20.9 | $7.94 | -62% |
| 2023 | $7.94 | $5.65 | -29% |
| 2024 | $5.65 | $7.06 | +25% |
| 2025 | $7.06 | $17.3 | +145% |
| 2026 YTD | $17.3 | $9.31 | -46% |
GLUE's yearly returns have swung widely, from +145% in 2025 to −62% in 2022. It's down 46% so far in 2026.